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The matrix protein (M1) of influenza A virus is generally viewed as a key orchestrator in the release of
influenza virions from the plasma membrane during infection. In contrast to this model, recent studies have
indicated that influenza virus requires expression of the envelope proteins for budding of intracellular M1 into
virus particles. Here we explored the mechanisms that control M1 budding. Similarly to previous studies, we
found that M1 by itself fails to form virus-like-particles (VLPs). We further demonstrated that M1, in the
absence of other viral proteins, was preferentially targeted to the nucleus/perinuclear region rather than to the
plasma membrane, where influenza virions bud. Remarkably, we showed that a 10-residue membrane targeting
peptide from either the Fyn or Lck oncoprotein appended to M1 at the N terminus redirected M1 to the plasma
membrane and allowed M1 particle budding without additional viral envelope proteins. To further identify a
functional link between plasma membrane targeting and VLP formation, we took advantage of the fact that M1
can interact with M2, unless the cytoplasmic tail is absent. Notably, native M2 but not mutant M2 effectively
targeted M1 to the plasma membrane and produced extracellular M1 VLPs. Our results suggest that influenza
virus M1 may not possess an inherent membrane targeting signal. Thus, the lack of efficient plasma membrane
targeting is responsible for the failure of M1 in budding. This study highlights the fact that interactions of M1
with viral envelope proteins are essential to direct M1 to the plasma membrane for influenza virus particle
release.
The late phase of the influenza A virus replication cycle is
marked by the occurrence of assembly and budding at the
plasma membrane of infected cells, which leads to the separa-
tion of virion and host cell membranes and ultimately results in
the production of infectious virus particles. This critical step is
a highly concerted process driven largely by protein-protein,
protein-lipid, and protein-nucleic acid interactions (34, 40). It
has been established for many years that four viral structural
components, namely, the matrix protein (M1), hemagglutinin
(HA), neuraminidase (NA), and M2, are actively involved in
the assembly and budding process (34, 35, 40), although the
identities of these inter- and intramolecular interactions and
regulatory mechanisms for influenza A virus assembly and
budding are unclear. It has also been suggested that interac-
tions of M1 with various cytoplasmic tails (CTs) of HA, NA,
and M2 are critical to drive the assembly and release of influ-
enza A virions from the surface of infected cells (1, 5, 10, 18,
25, 29, 30, 68). To date, these interactions have been largely
speculative because direct interactions have been demon-
strated only for M1 and M2 (5, 18, 29).
Early investigations into the budding machinery of influenza
A virus using vaccinia virus- and baculovirus-based expression
systems indicated that M1 was the only viral protein absolutely
required for the assembly of virus particles (14, 15, 26, 31).
This assumption seemed reasonable because M1, like the ret-
roviral Gag protein, is the most abundant protein in the virion
and lies directly underneath the lipid membrane, structurally
forming a bridge between viral envelope proteins and the sol-
uble viral RNA nucleoprotein (vRNP) complex (34, 35, 40).
Observations that M1 provided the major driving force for
influenza A virus budding were consistent with other findings
showing that neither HA nor NA is absolutely essential for
influenza virus budding (27, 42). However, a recent study in-
volving the use of a plasmid-based transfection system demon-
strated that HA and NA, not M1, were required for influenza
A virus assembly and budding (6). Surprisingly, the latter study
discovered that M1 expressed in transfected cells lacking HA
or NA could not form virus-like particles (VLPs). Therefore, it
was concluded that HA and NA glycoproteins, rather than M1
(6), are the driving force in influenza virus assembly and bud-
ding. A follow-up study further demonstrated that an interac-
tion between M2 and M1 is important for virion incorporation
of M1, as well as for productive virus assembly at virus budding
sites (5). Consistent with these reports using influenza H3N2
virus as a model system, a study analyzing neutralizing anti-
bodies present in survivors of the 1918 influenza pandemic
showed that H1N1 VLPs can be produced from expression of
HA and NA proteins only (65). Despite these recent advances
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in the understanding of influenza A virus budding, little is
known about the underlying mechanism of why the M1 protein
is incapable of forming extracellular VLPs. This information is
paramount for the resolution of the issue at hand: is there an
intrinsic deficiency in the initiation of the M1 budding process,
or are results simply dependent on the various expression sys-
tems used in each particular study (24, 34)?
In this study, we sought to explore the mechanism underly-
ing the apparent M1 defect in producing extracellular VLPs.
Our results showed that the lack of plasma membrane target-
ing is responsible for the failure of M1 to produce extracellular
particles when M1 is expressed alone. However, this M1 bud-
ding deficiency can be overcome through either the addition of
a heterologous membrane targeting signal or coexpression of
the M2 envelope protein, which in both cases directs M1 to the
plasma membrane and results in the efficient production of M1
VLPs. Our findings help to elucidate the mechanisms respon-
sible for the failure of influenza A virus M1 to bud from cells
as well as offering important new insights into fundamental
aspects of influenza A virus assembly and budding.
MATERIALS AND METHODS
Plasmid construction. To express influenza A viral proteins, the eukaryotic
expression vector pPRE was used under the control of both the cytomegalovirus
(CMV) immediate-early promoter and the bovine growth hormone polyadenyl-
ation signal (9). This specific plasmid contains the hepatitis B virus posttran-
scriptional regulatory element (PRE) to facilitate the export of mRNA into the
cytoplasm for optimal protein expression and has been used in characterization
of the budding machinery for various retroviruses, including HIV-1 (8, 22, 23, 41,
54). The influenza H1N1 A/WSN/33 virus reverse genetics system used in this
study was a gift from Eric Hoffmann at St. Jude Children’s Research Hospital,
Memphis, TN (16). For the construction of expression plasmids, DNA sequences
corresponding to the influenza virus M1 and M2 proteins were subcloned into
the pPRE expression vector, resulting in pM1 and pM2. For direct comparison
of M1 protein expression levels between pPRE and pCAGGS (an expression
vector driven by the chicken -actin promoter, widely used for expression of
influenza viral proteins), the M1 gene was also subcloned into pCAGGS (Add-
gene plasmid 11160; Addgene, Cambridge, MA), producing pCAGGS-M1. To
facilitate the detection of protein expression, an HA epitope tag was placed at
the C terminus of both M1 and M2. An M2 cytoplasmic tail mutant was gener-
ated by overlapping PCR in which the M2 tail was completely deleted from the
C terminus, and the resultant construct was designated pM2CT.
Various membrane-targeted M1 expression plasmids, pFyn-M1 and pLck-M1,
were derived from pM1 in the context of a PRE backbone by inserting annealed
oligonucleotides encoding the peptides Fyn (MGCVQCKDKE) and Lck (MG
CGCSSHPE) into the N terminus of the M1 protein in frame (66). A cysteine-
free pFyn-M1 expression plasmid was generated by exchanging two cysteine
residues for serine residues in the Fyn peptide by PCR-directed mutagenesis, and
the resultant construct was termed pFynSS-M1. In addition, two membrane
targeting green fluorescent protein (GFP) expression plasmids, pFyn-GFP and
pLck-GFP, were generated following the same methodology as was used in the
production of pFyn-M1 or pLck-M1.
For the construction of bimolecular fluorescence complementation (BiFC)
plasmids, sequences encoding either amino-terminal fragments (residues 1 to
173, VN) or carboxyl-terminal fragments (residues 155 to 238, VC) of the Venus
fluorescence protein were fused to both the N and C termini of M1 via a protein
linker (YPYDVPDYAASDIAAA) (22), which also included an HA tag se-
quence. The BiFC plasmids were termed M1-VN, VN-M1, M1-VC, and VC-M1,
respectively. The use of a flexible linker facilitates complementation of the split
fragments when they are brought into close proximity by the interacting proteins.
Detailed protocols, including primers and sequence information for each con-
struct, are available upon request. All plasmids were isolated using a Qiagen
Midiprep kit (Valencia, CA), and the specific mutations were confirmed by DNA
sequencing.
Cells and viruses. COS-1, 293T, and MDCK cells were cultured in Dulbecco’s
minimal essential medium (DMEM) supplemented with 10% fetal bovine serum.
Influenza viruses (H1N1 A/WSN/33) were generated using the reverse genetics
system developed by Hoffmann et al. (16). Viruses were harvested 72 h post-
transfection, and stock viruses were generated in MDCK cells.
Antibodies. Monoclonal mouse anti-HA antibody was purchased from Sigma-
Aldrich Co. (St. Louis, MO), and a monoclonal mouse anti-H1N1 M1 antibody
was obtained from AbD Serotec of MorphoSys US Inc. (Raleigh, NC). M2-
specific monoclonal antibody 14C2-S1-4 was kindly provided by Walter Gerhard
and Jan Erikson through the Wistar Institute. Goat anti-H1N1 M1 IgG conju-
gated to fluorescein isothiocyanate (FITC) was purchased from Virostat Co.
(Portland, ME). Polyclonal rabbit anti-GFP antibody, mouse anti--actin mono-
clonal antibody, donkey anti-goat IgG-horseradish peroxidase (HRP), donkey
anti-rabbit IgG-HRP, goat anti-mouse IgG-HRP, and goat anti-mouse IgG-
FITC were obtained from Abcam Inc. (Cambridge, MA).
Immunofluorescence assay (IFA) and confocal microscopy. MDCK cells in-
fected with influenza H1N1 A/WSN/33 virus or COS-1 cells transfected with the
plasmid DNAs as indicated above were fixed with 2% (wt/vol) paraformaldehyde
(Electron Microscopy Sciences, Hatfield, PA) followed by permeabilization with
0.2% (vol/vol) Triton X-100. Cells were further incubated with the appropriate
primary antibody directly conjugated with FITC or with the primary antibody
followed by secondary antibody conjugated to FITC and were then washed
briefly in phosphate-buffered saline (PBS) before being mounted on a slide with
Vectashield mounting medium (Vector Laboratories, Burlingame, CA). Sytox
orange (Invitrogen, Carlsbad, CA) and DAPI (4,6-diamidino-2-phenylindole;
Invitrogen) were used for staining nuclei of infected MDCK cells and transfected
COS-1 cells, respectively. Fluorescent imaging of fixed cells was done using a
FluoView FV300 confocal system (Olympus America Inc., Melville, NY)
equipped with an IX81 microscope. Digital images were processed with Adobe
Photoshop (version 6). All the images were taken under similar experimental
conditions (i.e., exposure time, magnification, and intensification), and process-
ing was also the same for all the images shown in this study.
For confocal microscopy analysis of M1 intracellular localization in MDCK
cells, the BiFC approach was used. MDCK cells grown on 12-well plates were
transfected with either M1-VN/M1-VC BiFC plasmids or individual BiFC plas-
mids (0.5 g of each plasmid). At 48 h posttransfection, transfected cells were
fixed, permeabilized, stained with DAPI (Invitrogen), and examined by the
procedure described above.
Virus budding assay. COS-1 cells in 60-nm plates were transfected with 3 g
of pM1 (or pCAGGS-M1) and its derivatives (pFyn-M1, pLck-M1, and pFynSS-
M1). For cotransfection, equal amounts of pM1 and pM2 or its mutant
(pM2CT) were used (3 g of each plasmid). The total amount of transfected
DNA in each sample was held constant using an empty vector lacking a coding
region to compensate for any variations. Transfection was performed by using
TransIT-LT1 (Mirus, Madison, WI) following the procedure outlined by the
manufacturer. For the preparation of VLPs, at 48 h or 72 h after transfection, the
culture medium was harvested and pelleted by centrifugation at 2,000  g for 20
min. Clarified supernatants were then layered through a 20% sucrose cushion
(PBS) and centrifuged at 100,000  g for 2 h at 4°C in a Beckman Ti rotor
(Beckman Coulter, Fullerton, CA). The pellet was resuspended on ice in 60 l
of PBS for 1 h followed by centrifugation at 2,000  g for 10 min at 4°C. Clarified
supernatants as VLPs were subject to further analysis. For the preparation of cell
lysates, cells were harvested at 48 h posttransfection and lysed in 600 l of lysis
buffer (25 mM Tris-HCl, pH 8.0, 150 mM NaCl, 1% deoxycholic acid, 1% Triton
X-100, 1 protease inhibitor cocktail). The cell lysates were prepared by cen-
trifugation at 2,000  g at 4°C for 10 min.
VLPs and cell lysates were separated on a 12.5% sodium dodecyl sulfate
(SDS)-polyacrylamide gel and transferred to a nitrocellulose membrane (Pierce,
Rockford, IL) followed by blocking in a PBS buffer containing 0.5% Tween 20
and 5% dry milk powder. Influenza virus proteins were detected by standard
Western blotting procedure coupled with the ECL system (Pierce, Rockford, IL)
with specific antibodies and corresponding secondary antibodies as described
above.
Two pharmacological inhibitors of protein palmitoylation, 2-bromopalmitate
(2BP) (Sigma-Aldrich) and cerulenin (Sigma-Aldrich), were used to address the
effect of palmitoylation on VLP release by palmitoylated M1 budding. COS-1
cells were transfected with pFyn-M1 as described above. 2BP at a concentration
of 50 M, cerulenin at a concentration of 1 g/ml, or dimethyl sulfoxide (DMSO;
no-drug control) was maintained throughout the period of the culture, and
SDS-PAGE/Western blot analysis of either M1 proteins or the endogenous actin
derived from these cultures was performed as described above.
Protease protection assay. Purified VLPs derived from COS-1 cells transfected
with Fyn-M1 were split into three equivalent aliquots. Two aliquots were treated
with TPCK (tosylsulfonyl phenylalanyl chloromethyl ketone)-trypsin (Sigma-
Aldrich) in the presence or absence of 1% Triton X-100 for 30 min at 37°C. The
third aliquot was treated with only 1% Triton X-100 under the same experimen-
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tal conditions. All samples were analyzed by SDS-PAGE and Western blotting
with anti-M1 monoclonal antibody.
RESULTS
Failure of M1 to produce extracellular VLPs. Transient
transfection coupled with Western blot analysis was used to
address whether the expression of M1 protein could drive VLP
formation without additional viral proteins present. Transfec-
tion of COS-1 by the two M1 expression plasmids, pCAGGS
and PRE (9), resulted in similar levels of M1 protein expres-
sion, respectively, but failed to produce any detectable VLPs
(Fig. 1B). Our experiments with pCAGGS-M1 in COS-1 cells
replicated the M1 protein budding deficiency that was de-
scribed previously by Chen et al. under their experimental
conditions involving 293T and HeLa cells (6). Thus, results
from our studies support the previous observation that the M1
protein alone is insufficient to bud and form VLPs (6). It also
suggests that the M1 budding deficiency observed is not cell
type dependent. Notably, the quantities of M1 expression in
the two vectors were indistinguishable; thus, we used only M1
in the PRE vector for further experiments.
M1 localizes in the nucleus and perinuclear region of the
transfected cells in the absence of other viral proteins. During
the late stage of viral replication in HIV-1 and other enveloped
viruses, e.g., Ebola virus and vesicular stomatitis virus (VSV),
newly synthesized Gag or matrix proteins are targeted to the
plasma membrane of infected cells, where they self-oligomer-
ize and colocalize at lipid rafts assembling into immature viri-
ons (19, 33, 38, 49, 52, 53, 58, 62, 69). To determine if M1’s
inability to release into VLPs is caused by inappropriate tar-
geting of M1 in the absence of other viral proteins, we stained
permeabilized COS-1 cells expressing M1 at 48 h posttransfec-
tion with an FITC-conjugated antibody for M1. The results
showed that M1 protein localizes primarily to the nucleus and
perinuclear region with no apparent accumulation at the
plasma membrane (Fig. 1C), much like budding-defective ret-
roviral Gag mutants that lack the plasma membrane-binding
domain required for Gag assembly and release (36, 37, 39, 50,
64). A similar M1 localization pattern without the plasma
membrane staining was also observed at both 24 h and 72 h
posttransfection (data not shown).
We also characterized the subcellular localization of M1 in
MDCK cells, as they are widely used for studying influenza
virus replication and infectivity. In this experiment, we em-
ployed a BiFC assay to study M1 subcellular localization. We
used the BiFC approach rather than an indirect immunofluo-
rescence assay (IFA) to locate M1 in MDCK cells because
repeated transfection of MDCK cells using M1 expression
plasmids failed to reveal any detectable signals when at-
tempted in IFA (using anti-M1 antibody conjugated with
FITC). We feel that this is probably due to a low transfection
efficiency of MDCK cells. The BiFC assay by nature has
greater sensitivity, exhibiting detection of fluorescence comple-
mentation at extremely low levels of protein expression (as low
as 25 to 100 copies per cell) (17). This sensitive technique is
designed for visualizing protein interactions and localization in
living cells and as such seemed to us a wise choice for exper-
imentation (17). BiFC M1-VN and M1-VC fusion constructs
were generated in which VN (N-terminal 173 residues of Ve-
nus) and VC (C-terminal 83 residues of Venus) segments were
each fused to the carboxy terminus of the M1 protein (Fig.
2A). Presumably as an oligomeric complex, M1 in MDCK cells
transfected with BiFC M1-VN/M1-VC plasmids primarily lo-
calized to the nucleus and perinuclear region with no signifi-
cant accumulation at the plasma membrane (Fig. 2B). We also
generated VN-M1 and VC-M1 constructs in which VN and VC
segments were each fused to the amino terminus of the M1
protein. Transfection of MDCK cells with BiFC VN-M1/
VC-M1 resulted in a similar M1 localization in the nucleus/
perinuclear region (data not shown). However, in contrast to
the pattern of M1 localization observed when M1 was ex-
pressed alone, M1 in the context of H1N1 virally infected
MDCK cells, which showed significant accumulation of M1 at
the plasma membrane (Fig. 2C), in addition to some nuclear
and perinuclear localization as observed previously in our
transfection experiment involving only M1. M1 localization to
the plasma membrane in virally infected cells reinforces the
idea that factors such as viral envelope proteins (HA, NA, and
M2) are needed for transportation of M1 to the cell surface as
suggested previously (1, 5, 10, 18, 25, 29, 30, 68). Based on
these data, it is evident that M1 alone cannot be trafficked to
the plasma membrane.
In summary, data indicate that M1, in the absence of other
viral proteins, localizes in the nucleus and the perinuclear
FIG. 1. M1 alone is not sufficient for extracellular VLP formation.
(A) Schematic diagram of M1 expression constructs. An HA epitope
tag (YPYDVPDYA) was appended in frame to the C terminus of the
M1 protein in pPRE and pCAGGS vectors, producing pM1 and
pCAGGS-M1, respectively. (B) VLP production by COS-1 cells trans-
fected with pM1 and pCAGGS-M1 plasmids. VLPs and cell lysates
were analyzed by Western blotting with an anti-HA monoclonal anti-
body. (C) Representative M1 subcellular localization images in trans-
fected COS-1 cells expressing M1 protein. At 48 h posttransfection,
COS-1 cells transfected with either pM1 or empty vector (mock) plas-
mids were fixed, permeabilized, and stained with goat anti-M1 IgG-
FITC. Nuclei were stained with DAPI. M1 localization was then ex-
amined using confocal microscopy at an 60 magnification.
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region, not the plasma membrane where the whole influenza
virus assembles and buds. Thus, a deficiency in plasma mem-
brane targeting by M1 best explains the failure of M1 to pro-
duce extracellular VLPs as shown here and elsewhere (6). This
could be the result of a defective membrane targeting domain
or the lack of an inherent membrane targeting signal for in-
fluenza virus M1 protein.
Production of extracellular VLPs by rational targeting of
M1 to the plasma membrane. Based on our results, we further
hypothesized that targeting of M1 to the plasma membrane
could result in M1 budding into VLPs. We were particularly
interested in the possibility of VLP formation through either
M1 interactions with other viral proteins or nonviral factors
such as heterologous membrane targeting signals. To test our
hypothesis, we took advantage of two well-characterized
plasma membrane targeting domains (66): a 10-residue myris-
toylated and palmitoylated peptide derived from the Fyn
oncoprotein and a 10-residue myristoylated and palmitoylated
peptide derived from the Lck oncoprotein. For the purpose of
this test, each 10-residue membrane targeting peptide was
fused to the M1 protein at the N terminus, resulting in two
constructs which we designated Fyn-M1 and Lck-M1 (Fig. 3A).
Once our constructs were completed, we first determined
whether or not our targeting strategy had the intended effect.
Remarkably, both Fyn-M1 and Lck-M1 efficiently trafficked to
the plasma membrane in transfected COS-1 cells. This con-
trasted greatly with earlier transfections of wild-type (WT) M1,
where a nuclear/perinuclear localization pattern had been ob-
served (Fig. 3B). We next asked whether shifting M1 to the
plasma membrane through the use of Fyn or Lck targeting
domains had the ability to result in extracellular VLP forma-
tion from M1 budding. Both Fyn-M1 and Lck-M1 generated
VLPs, with Fyn-M1 VLP formation being the more prevalent
(Fig. 4A). Again, WT M1 failed to produce VLPs under the
same experimental conditions as those used for Fyn-M1 and
Lck-M1, which supports our previous results (Fig. 1B). Our
data clearly indicate that the rational targeting of M1 to the
plasma membrane can result in the production of extracellular
VLPs. The results also suggest that various 10-residue mem-
brane targeting domains can functionally replace the role of
viral envelope proteins for the targeting of M1 to the plasma
FIG. 2. Comparative studies of M1 localization patterns between
transient transfection and virus infection in MDCK cells. (A) Sche-
matic representation of M1 BiFC constructs (M1-VN and M1-VC).
Venus fragments VN (N-terminal 173 residues) and VC (C-terminal
83 residues) were fused in frame to the C terminus of M1, which
resulted in pM1-VN and pM1-VC, respectively. “L” indicates a linker
sequence (YPYDVPDYAASDIAAA) inserted between VN or VC
fragments and M1. A portion of the linker is an HA tag sequence.
(B) M1 subcellular localization images in MDCK cells expressing BiFC
M1-VN and M1-VC fusion proteins. At 48 h posttransfection, MDCK
cells transfected with BiFC M1-VN/M1-VC plasmids or M1-VC plas-
mids (negative control) were fixed, stained with DAPI, and imaged
with a confocal microscope at an 60 magnification. Two representa-
tive BiFC images of M1 localization are shown (M1-M1a and M1-
M1b). (C) M1 subcellular localization images of virus-infected MDCK
cells. At 48 h postinfection, MDCK cells infected with influenza H1N1
A/WSN/33 virus were fixed, permeabilized, and stained with goat anti-
M1 IgG-FITC. Sytox orange was used for staining nuclei of infected
cells. M1 localization was examined with a confocal microscopy at
an 100 magnification.
FIG. 3. Membrane targeting domains redirect M1 to the plasma
membrane. (A) Schematic representation of two membrane targeting
domains derived from Fyn and Lck oncoproteins that were appended
to the M1 N terminus. (B) Representative M1 subcellular localization
images in COS-1 cells expressing M1 or Fyn-M1 or Lck-M1. At 48 h
posttransfection, COS-1 cells individually transfected with pM1, pFyn-
M1, pLck-M1, and empty vector (mock) were fixed, permeabilized,
and stained with goat anti-M1 IgG-FITC. Nuclei of COS-1 cells were
stained with DAPI. M1 localization among these cells was then exam-
ined by confocal microscopy at an 60 magnification.
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membrane. In summary, results of these experiments further
support our hypothesis that the lack of a membrane targeting
signal within M1 is responsible for M1 budding failure.
We next chose to examine whether the VLPs assembled by
Fyn-M1 or Lck-M1 were specifically regulated by fatty acyla-
tion of the M1 protein (myristoylation and palmitoylation)
through the introduced 10-residue membrane targeting pep-
tides. We focused our study on the potential contribution of
palmitoylation in induced M1 budding because the viral enve-
lope proteins (HA, NA, and M2) that interact with M1 are not
myristoylated (40), whereas palmitoylation of M2 and HA has
been reported previously (55, 56, 59–61). Several early studies
have also suggested a role for palmitoylation in influenza virus
assembly (1, 7, 10, 20). Because Fyn-M generates VLPs with
greater efficiency than does Lck-M1, it was selected for further
experimentation. We constructed Fyn-M1 proteins devoid of
palmitoylation acceptors by replacing two N-terminal cysteine
residues with serine residues, and the resultant construct was
designated FynSS-M1 (Fig. 4B). The absence of cysteine in the
Fyn membrane targeting domain should inhibit the addition of
the 16-carbon fatty acid palmitate (palmitoylation), as demon-
strated in previous studies (44–46). Remarkably, FynSS-M1
failed to generate extracellular VLPs, although M1 intracellu-
lar protein production levels were comparable to those ob-
served in the Fyn-M1 system (Fig. 4B). In addition to this
site-directed mutagenesis approach, we also utilized chemical
inhibitors of protein palmitoylation to determine the func-
tional significance of palmitoylation in driving Fyn-M1 budding
(46). Two pharmacological inhibitors of protein palmitoyl-
ation, 2BP and cerulenin, were used. As demonstrated in Fig.
4C, 2BP showed no obvious effect on the expression levels of
intracellular M1 protein as well as endogenous actin protein
FIG. 4. Production of extracellular M1 particles by membrane-targeted M1 proteins. (A) VLP production by COS-1 cells transfected with pM1
or pFyn-M1 or pLck-M1 plasmid. M1 VLPs and cell lysates were analyzed in a Western blot assay with anti-M1 monoclonal antibody. (B) VLP
production by COS-1 cells transfected with Fyn-M1 or FynSS-M1 mutant defective in protein palmitoylation. VLPs and cell lysates were analyzed
by Western blotting with anti-M1 monoclonal antibody. (C) VLP production by COS-1 cells transfected with Fyn-M1 in the absence or presence
of protein palmitoylation inhibitors, 2-bromopalmitate (2BP; Sigma-Aldrich) and cerulenin (Sigma-Aldrich). VLPs and cell lysates were analyzed
by Western blotting with anti-HA monoclonal antibody (Sigma-Aldrich). Cell lysates derived from the 2BP treatment and the DMSO control were
also analyzed for the expression of endogenous -actin proteins with antiactin monoclonal antibody (Abcam). (D) Trypsin digestion of VLPs.
Purified VLPs derived from COS-1 cells transfected with Fyn-M1 were treated with TPCK-trypsin (Sigma-Aldrich) in the presence or absence of
1% Triton X-100 for 30 min at 37°C. Fyn-M1 VLPs were also treated with 1% Triton X-100 without TPCK-trypsin under the same experimental
conditions. M1 protein was then visualized by Western blotting with anti-HA monoclonal antibody. (E) Representative M1 subcellular localization
images in COS-1 cells expressing Fyn-M1 with or without 2BP treatment or Fyn-M1SS. At 48 h posttransfection, COS-1 cells individually
transfected with pFyn-M1 (in the presence or absence of 2BP) and pFyn-M1SS were fixed, permeabilized, and stained with goat anti-M1 IgG-FITC.
Nuclei of COS-1 cells were stained with DAPI. M1 localization among these cells was then examined by confocal microscopy at an 60
magnification. (F) Representative GFP subcellular localization images in COS-1 cells expressing Fyn-GFP and Lck-GFP and VLP production by
COS-1 cells transfected with pFyn-GFP or pLck-GFP plasmid. GFP VLPs and cell lysates were analyzed in a Western blot assay with anti-GFP
polyclonal antibody (Abcam).
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compared to DMSO control but instead completely blocked
Fyn-M1 particle release. This indicates that palmitoylation
specifically is involved in the regulation of Fyn-M1 particle
release. In contrast, cerulenin exerted no obvious effect on
Fyn-M1 particle budding. At present, we do not know how to
explain the different activities exhibited by these two inhibitors
but speculate that it may reflect their mechanisms of action:
2BP is a nonmetabolizable palmitate analog that blocks palmi-
tate incorporation into proteins, while cerulenin inhibits pro-
tein palmitoylation by targeting some groups of palmitoyl acyl-
transferase, which catalyzes the addition of palmitate to
cysteine residues of protein through thioester linkages (46).
As an additional verification of the authenticity of Fyn-M1
assembly, we performed a protease digestion experiment on
Fyn-M particles in the presence or absence of a detergent
(Triton X-100). It has been well established that extracellular
VLPs completely enveloped by the lipid bilayer are resistant to
protease digestion unless the bilayer is disrupted with a deter-
gent (4, 11, 13, 34, 63). To examine whether the Fyn-M1 VLPs
released from our experimental conditions were encased in the
plasma membrane, purified Fyn-M1 particles were digested
with trypsin in the presence or absence of 1% Triton X-100 and
analyzed by Western blotting using an anti-M1 monoclonal
antibody (Fig. 4D). The M1 proteins were completely digested
with trypsin in the presence of the detergent. In contrast, no
digestion of M1 protein was observed in the absence of the
detergent (Fig. 4D). These results indicate that extracellular
VLPs produced by Fyn-M1 in COS-1 cells were completely
surrounded by the lipid membrane, suggesting that Fyn-M1
mimics WT M1 in the presence of viral envelope proteins in
that it is directed to the plasma membrane, assembled, and
released.
We also performed a series of control experiments that
enabled us to examine whether a mutated Fyn membrane
targeting peptide or the administration of 2BP inhibitors could
block M1 transportation to the plasma membrane, thereby
inhibiting the formation of M1 VLPs. As demonstrated in Fig.
4E, neither M1 directed by the mutated Fyn peptide nor M1 in
the presence of 2BP resulted in a significant accumulation of
M1 at the cell surface compared to WT Fyn-M1 proteins. This
result coupled with the above data (Fig. 3B and C) further
highlights the specificity of palmitoylation in directing M1 to
the plasma membrane and subsequently causing M1 VLP re-
lease.
Lastly, we were interested in determining whether any sol-
uble protein such as GFP has the ability to bud from cells when
directed specifically to the plasma membrane. For this exami-
nation, we generated two GFP fusion constructs in which Fyn or
Lck membrane targeting peptide was fused to the N terminus of
GFP. Our resulting constructs were named Fyn-GFP and Lck-
GFP, respectively. Transfection of COS-1 cells with Fyn-GFP and
Lck-GFP plasmids shifted a significant portion of the GFPs to the
plasma membrane; however, none of them produced any detect-
able GFP particles (Fig. 4F). The results further support the idea
that M1 has an inherent budding ability as well as our hypothesis
that M1 fails to bud into VLPs primarily due to the lack of an
inherent membrane targeting signal.
Coexpression of the M2 protein, not M2 cytoplasmic tail
(CT) deletion, redirects M1 to the plasma membrane and
facilitates M1 budding. It has been shown that two viral enve-
lope proteins (HA and NA) are required for budding of M1
from the cell, and the coexpression of HA and NA can effi-
ciently incorporate M1 into extracellular VLPs (6, 24, 43).
Knowing this to be the case, we asked whether coexpression of
the M2 protein could independently promote M1 budding into
VLPs without HA and NA proteins. We were particularly
interested in determining whether the established M1-M2 in-
teraction (5, 18, 29, 30) was capable of shifting M1 to the
plasma membrane; subsequently resulting in the formation of
M1 particles. As such, an M2 expression construct was gener-
ated in the PRE vector with an HA epitope tag appended to
the C terminus. The same strategy was also used to generate an
M2 mutant with complete deletion of the CT, termed M2CT.
This M2 mutant served as a negative control, as previous stud-
ies showed that the deletion of the CT in M2 disrupted normal
M1-M2 interactions and inhibited virus assembly (5, 18, 29,
30). We also generated a BiFC M2-VC construct in which the
VC segment of Venus was fused to the C terminus of our M2
protein, and this construct was used in combination with
M1-VN in BiFC to localize the M1-M2 complex in living cells
(Fig. 5A).
We first determined if M2 could rescue M1 budding into
extracellular VLPs independently of HA and NA proteins. As
demonstrated in Fig. 5B, coexpression of M2 protein with M1
efficiently generated VLPs. In contrast, VLP release was not
detected in cells transfected with both M2CT and M1, al-
though comparable amounts of M1 and M2CT proteins at the
intracellular level were observed. These results indicated that
the M2 protein is capable of rescuing M1 to form extracellular
VLPs, which is likely mediated through a specific M1-M2 in-
teraction. It should be noted that the expression of M2 protein
alone did not result in any detectable M2 particles during our
experimentation (data not shown). We next compared M1
localization patterns among COS-1 cells transfected with ei-
ther M1, M1 and M2, or M1 and M2CT plasmids by using an
indirect immunofluorescence assay featuring the use of an
anti-M1 monoclonal antibody. When M1 and M2 were co-
transfected, the M1 intracellular localization pattern was
greatly altered compared to cells transfected with M1 only or
cells cotransfected with M1 and CT-deleted M2 (M2CT) (Fig.
5C). Two representative images of M1 localization patterns
from the M1/M2 cotransfection experiment are shown in Fig.
5C. These images demonstrate a shift in M1 localization from
the nucleus/perinuclear region to the plasma membranes as
well as to some internal cellular compartments. In contrast,
coexpression of M2CT with M1 failed to redirect M1 out of
the nucleus/perinuclear region, resulting in an M1 localization
pattern that is similar to that observed in cells expressing M1
alone. The Western blot analysis of duplicate samples used for
the indirect immunofluorescence assay (Fig. 5C) revealed that
M1 and M2 or M2 mutant proteins are expressed (data not
shown). To complement our cotransfection experiments, we
also used the BiFC approach to monitor M1 localization as a
function of M1-M2 complex formation. Notably, BiFC data
(Fig. 5C) largely recapitulate the M1 localization pattern ob-
served in indirect immunofluorescence experiments involving
coexpression of M1 and M2 proteins (Fig. 5C): M1 is shifted
out of the nucleus to the plasma membrane as well as other
cellular compartments. These results indicate that M2 protein
can efficiently target M1 through specific protein-protein in-
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teractions to the assembly site (e.g., plasma membrane), which
in turn promotes M1 incorporation into virus particles. Thus,
the data continuously support our hypothesis that the lack of a
membrane targeting signal within M1 accounts for its failure to
redirect M1 to the plasma membrane to produce extracellular
VLPs.
DISCUSSION
Previous studies from Chen and colleagues have demon-
strated that influenza A virus requires expression of the enve-
lope proteins for budding of intracellular M1 from the cells (6).
The current studies support these findings and further demon-
strate for the first time that the lack of plasma membrane
targeting is responsible for the failure of M1 to generate ex-
tracellular particles in the absence of other viral proteins. The
present study also reveals for the first time that redirecting M1
to the plasma membrane, either by a heterologous membrane
targeting domain or through interaction with the envelope
protein (M2), can result in the production of M1 particles.
Taken together, the results discussed here and elsewhere (5, 6)
collectively highlight the importance of viral envelope proteins
in directing M1 to the plasma membrane and indicate that
multiple interactions involving M1 and viral envelope proteins
are essential to drive influenza virus particle budding.
Results of our experiments reveal several interesting aspects
of influenza virus assembly and budding. First, the correlation
between the efficiency of membrane targeting and M1 budding
competency may help to resolve the current debate regarding
the role of M1 in influenza virus budding. Previous studies
using recombinant baculovirus or vaccinia virus systems solely
expressing M1 showed that M1 was capable of assembly and
production of extracellular VLPs (14, 15, 26). Taking into
account the current observations, we can speculate that bacu-
lovirus and vaccinia virus expression systems may produce
some unknown factors that target M1 to the plasma membrane
of cells, which in turn promotes M1 particle budding. However,
we cannot rule out the other possibilities, such as M1 “leaking”
from infected cells as they undergo necrosis, as proposed pre-
viously in the vaccinia virus expression system (6). Second, the
observation that M1 is incorporated into VLPs by M2 in the
absence of HA and NA proteins appears to continue a theme
established by previous studies revealing that multiple and
often redundant pathways occur in the influenza virus budding
process and that only one envelope protein is required for
influenza virus assembly and budding (1, 12, 20, 21, 27, 32, 42).
Specifically, these studies showed that none of the three viral
envelope proteins (HA, NA, and M2) are absolutely required
for influenza A virus budding, and virus particles lacking either
FIG. 5. Coexpression of M2 shifts M1 to the plasma membrane and allows M1 particle budding. (A) A schematic diagram of the expression
constructs of M2 (pM2) and M2 mutant (pM2CT) lacking the entire CT domain as well as our BiFC M2-VC fusion construct. The experimental
approach for the generation of these constructs has been detailed in Materials and Methods. (B) VLP production by COS-1 cells transfected with
pM1 plasmid, either alone or in combination with pM2 or pM2CT. At 72 h following transfection, supernatant medium and cellular lysates from
each culture were individually collected and VLPs were prepared by ultracentrifugation. Equal amounts of VLP and lysate samples were run on
different gels with the same concentration (12.5% SDS-PAGE) under similar experimental conditions, followed by transferring of proteins to
different nitrocellulose membranes. Membranes were then probed separately with M1- or M2-specific antibody and exposed to different films for
the visualization of protein expression. Note that Ml and M2/M2CT protein bands were placed together arbitrarily according to their molecular
weights by comparison with protein markers. Similar results were also obtained in experiments involving the separation of equal amounts of VLPs
and cellular lysates on the same gel/membrane followed by cutting of the membrane into two different pieces corresponding to the migration
distances of Ml and M2/M2CT proteins according to the position of molecular weight markers. The separated membrane pieces were then
individually analyzed in Western blotting via protein-specific antibodies (Ml and M2), respectively. (C) Subcellular localization patterns of M1
protein in transfected COS-1 cells expressing M1, M1 and M2, and M1 and M2CT and subcellular localization patterns of M1-M2 complex in
transfected COS-1 cells expressing M1-VN and M1-VC. At 48 h posttransfection, COS-1 cells were fixed, permeabilized, and stained with goat
anti-M1 IgG-FITC. For the BiFC experiment, staining with anti-M1 IgG-FITC was not needed. Nuclei of COS-1 cells were stained with DAPI.
Two representative images of M1 localization, M1M2a and M1M2b, are shown from cells coexpressing M1 and M2 proteins.
VOL. 84, 2010 INFLUENZA A VIRUS M1 BUDDING DEFECT 4679
viral envelope proteins or the cytoplasmic tails of both HA and
NA can be formed and released, although such particles are
not infectious. Our observations presented in this paper sup-
port these earlier studies regarding considerable redundancy in
influenza virus budding and further highlight the fact that only
a single interaction between M1 and one viral envelope protein
such as M2 is required to direct intracellular M1 to the plasma
membrane and to produce virus particles. Finally, our finding
that the M1 protein assembles and forms extracellular parti-
cles, when aided by a 10-residue targeting peptide, suggests
that M1 may have the ability to induce membrane curvature,
undergo envelopment, and achieve budding into extracellular
VLPs once transported to the plasma membrane. Although
our hypothesis needs to be tested experimentally in the future,
there are several lines of evidence in support of this hypothesis.
Previous studies of diverse M1 mutants have demonstrated
that M1 is critical in influenza virus budding and particle re-
lease, given that the introduced mutations did not disrupt its
interactions with viral envelope proteins (2, 3, 28, 34, 47). A
recent study of the foamy virus (a retrovirus) Gag demon-
strated that the Gag particle budding process was still depen-
dent on the intact PSAP L domain within foamy virus Gag and
the associated recruitment of the class E vacuolar protein
sorting (VPS) machinery to the budding site (66), even though
Fyn and Lck membrane targeting peptides had been added to
Gag in this study. Furthermore, it has been shown in various
studies that the two peptides used in our study direct various
fusion proteins with different biological features exclusively to
the lipid rafts of the plasma membrane, not the extracellular
environment (44, 45). The results showing that Fyn-GFP fu-
sion proteins efficiently transport to the plasma membrane but
fail to produce any detectable GFP particles also support the
statement of M1 having an inherent budding ability.
Our observation that M1, in the absence of other viral pro-
teins, was primarily targeted to the nucleus/perinuclear region
initially came as a surprise but seems logical since M1 contains
a well-documented nuclear signal, as demonstrated by several
previous studies involving different approaches (1, 51, 57, 67).
It should be noted that our documented findings on M1 local-
ization differ substantially from those reported previously using
the M1-expressing vaccinia virus system (10, 25, 67). These
previous studies showed that M1 protein, when expressed
alone, was associated with cellular membranes, including the
plasma membrane. The association of M1 with the plasma
membrane that was observed in the vaccinia virus-based ex-
pression system seems to indicate that the M1 protein in this
system has the ability to produce extracellular VLPs as re-
ported previously (14, 15). As discussed above, we reason that
membrane targeting by M1 in the vaccinia virus expression
system was not likely mediated by the M1 protein itself.
Rather, we believe that some unknown factors produced by
vaccinia viruses transport M1 to the plasma membrane, caus-
ing release of the M1 particle, although this hypothesis has not
yet been tested. It should be pointed out that our data do not
argue against the presence of multiple membrane-binding do-
mains within the M1 protein as other previous studies have
suggested (25, 48, 57). Instead, our results suggest that when
M1 is targeted to the plasma membrane via envelope protein
interactions, M1 depends on these distinctive membrane-bind-
ing domains to synergistically induce membrane curvature, un-
dergo envelopment, and release M1 VLPs as we demonstrated
in our Fyn-M and Lck-M1 systems.
In summary, we have shown that the lack of plasma mem-
brane targeting is responsible for the failure of M1 in gener-
ating extracellular VLPs. Our results strongly indicate that M1
may not possess an inherent membrane targeting signal, as has
been reported for retroviral Gags and other viral matrix pro-
teins (19, 33, 38, 49, 52, 53, 58, 62, 69). This deficiency high-
lights interactions of M1 with influenza virus envelope proteins
as being essential for the directing of M1 to the plasma mem-
brane for particle release. By overcoming the defects for traf-
ficking and VLP formation through membrane targeting pep-
tides, M1 can now be characterized in this relatively simple
system to identify individual functional domains responsible
for various steps in the influenza virus budding process.
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